Approx. 257 million people worldwide live with hepatitis B. While treatments exist to manage the virus, there’s currently no definitive cure. #WorldHepatitisDay underscores the urgent need to accelerate research & innovation in the fight against #hepatitisB. #HepatitisAwareness

We’re proud to deliver personalized #biospecimens & research services to #lifescience & #diagnostics organizations that are enhancing and extending lives through medical breakthroughs: #ELEVATINGscience #Biospecimens #SmarterScience

Subcellular fractions offer an efficient and cost-effective alternative to whole-cell systems. But with so many options, how do you know which best fits your needs? Download our guide on choosing the right test systems for your #ADME studies:

Just because two #biospecimens seem the same, it doesn’t mean they are. Lack of quality #biospecimens resulted in 60% of researchers questioning their findings and 81% limiting the scope of their work.* How can you avoid these issues? Learn more:

Jordan Hunter, PhD shares insights on manufacturing hurdles for the #CellandGeneTherapy / #ATMP industry in a roundtable with Pharma's Almanac, discussing scalability, supply chain fragility, and how to overcome these obstacles:

Understanding non-CYP metabolism requires a strategic, structure-informed approach. From #hepatocytes to recombinant #enzymes, knowing when to go broad — and when to go deep — can make or break your study. Dive into practical insights from Dr. Ogilvie:

#Science & #art both begin with a bold stroke. In honor of World Watercolor Month, we’re celebrating the beauty of exploration through both brush and bench with this #ScienceArt piece inspired by #Okeeffe. Get it (and others) here:

Choosing the right cellular starting and raw materials vendor for your #CellandGeneTherapy is crucial. Discover three key strategies to evaluate and find the perfect fit. ➡️ #CellTherapy #GeneTherapy #AdvancedTherapies #QualityControl #VendorSelection

A recent customer study using human #glioblastoma tissue provided insights into the role of disulfidptosis in glioma progression and its potential as a therapeutic target: #GlioblastomaAwareness #GlioblastomaAwarenessDay

Our presentation from last month’s forum on the business & science of #exosomes by John Ludlow, PhD, Sr. Scientific Advisor for Exosomes at BioIVT, is now available online!

Disease is always deeply personal, affecting all of us at some point in life. This reality drives our mission to support researchers worldwide in advancing #PersonalizedMedicine, ensuring they have the highest quality biospecimens and data. #ItsPersonal #WhyWeDoWhatWeDo

Did you know that BioIVT offers the same transporter vesicles that we use in our own vesicle assays? The vesicles, manufactured by GenoMembrane, are particularly ideal for studying efflux (ABC) #drugtransporters:

Please join us in welcoming Kent Grindstaff, PhD as our new Consulting Director. We are excited to have him on board and look forward to the valuable contributions he will make to our team! Learn more about Kent’s experience:

Several of the presentations from our #neuroscience symposium in South San Francisco last week are now available online! Access the recordings and slides: #NeuroscienceResearch #Biomarkers #DrugDevelopment #BioIVTNeuroExcellence

#Liquidbiopsy is reshaping precision medicine, extracting genetic, proteomic, and epigenetic data from blood, urine, and potentially other biofluids such as saliva, cerebrospinal fluid, sweat, and even tears. Learn more:

As we discuss the FDA’s Roadmap to Reducing Animal Testing in Preclinical Safety Studies (, we thought we would highlight a recent publication about a novel milli-fluidic human liver tissue chip (LTC) designed by @JavelinBiotech:

The FDA’s Roadmap to Reducing Animal Testing in Preclinical Safety Studies outlines a 3–5 year action plan to make animal studies the exception rather than the rule. Learn more about the roadmap and our ability to support New Approach Methodologies (NAMs):

While trends come and go, access to research-quality #biospecimens should never be out of reach. That’s why BioIVT is bringing back 2015 pricing on our #ASTERAND® high-quality, ethically sourced, disease-state tissue:

A new #grant program with the goal of reducing adverse drug interactions allows researchers to apply for free lots of cryosuspension #hepatocytes that have been selected and characterized for non-CYP metabolism research. Learn more and submit a proposal:

Download our #ScientificPoster: “Impact of Donor Demographics and Mobilization Regimens on WBC and CD34+ Cell Yields”: #HSPCs #StemCells #ProgenitorCells #CellTherapy #GeneTherapy